Clinical Trials Browser

Interventional × sacituzumab govitecan × CNS × Clear all

NCT06462092 2025-09-29

Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Cancer

Phase 1/2 Recruiting

Breast Neoplasms, Meningeal Carcinomatosis

NCT04559230 2025-08-05

Sacituzumab Govitecan in Recurrent Glioblastoma

Phase 2 Recruiting

Glioblastoma

NCT06401824 2025-05-06

Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases

Phase 2 Recruiting

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT04647916 2025-04-24

Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases

Phase 2 Active not recruiting

Brain Neoplasms

NCT03995706 2024-09-04

Neuro/Sacituzumab Govitecan/Breast Brain Metastasis/Glioblastoma/Ph 0

Phase EARLY_PHASE1 Completed

Glioblastoma

NCT06462079 2024-06-17

Sacituzumab Govitecan Combined With Head Radiotherapy for Her2-negative Breast Cancer Brain Metastases

Phase 2 Not yet recruiting

Brain Neoplasms, Breast Neoplasms

NCT01631552 2021-08-12

Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

Phase 1/2 Completed

515 enrolled 28 charts 2 FDA

BreastCNSGastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms